CIOLI, PATRIZIA
 Distribuzione geografica
Continente #
NA - Nord America 313
EU - Europa 232
AS - Asia 94
Totale 639
Nazione #
US - Stati Uniti d'America 313
IT - Italia 65
IE - Irlanda 45
SG - Singapore 40
CN - Cina 33
DE - Germania 25
SE - Svezia 24
UA - Ucraina 24
HK - Hong Kong 16
FI - Finlandia 12
GB - Regno Unito 10
RU - Federazione Russa 10
BE - Belgio 7
CZ - Repubblica Ceca 3
CH - Svizzera 2
IN - India 2
UZ - Uzbekistan 2
AT - Austria 1
FR - Francia 1
KR - Corea 1
LU - Lussemburgo 1
PL - Polonia 1
RO - Romania 1
Totale 639
Città #
Chandler 79
Dublin 45
Ann Arbor 41
Perugia 38
Singapore 34
San Mateo 24
Munich 17
Hong Kong 16
Wilmington 16
Altamura 14
Boardman 14
Jacksonville 14
Beijing 12
Medford 12
Princeton 12
Santa Clara 12
Lawrence 11
Brussels 7
Woodbridge 6
Falls Church 4
Helsinki 4
Andover 3
Corridonia 3
Des Moines 3
Los Angeles 3
Redmond 3
Saint Petersburg 3
Amelia 2
Hyderabad 2
Olomouc 2
Redwood City 2
San Paolo di Civitate 2
Ashburn 1
Brno 1
Bucu 1
Changsha 1
Dallas 1
Frankfurt Am Main 1
Hanover 1
Houston 1
Mountain View 1
Napoli 1
Norwalk 1
Nürnberg 1
Seoul 1
Terni 1
Totale 474
Nome #
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 116
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 83
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 75
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 63
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 52
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 44
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 43
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 42
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 40
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 40
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 39
Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. 33
Totale 670
Categoria #
all - tutte 3.045
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.045


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202039 0 0 0 0 5 5 4 3 3 11 5 3
2020/202191 1 7 3 4 35 5 9 2 11 3 7 4
2021/2022117 2 17 0 5 7 3 2 30 4 9 26 12
2022/2023204 13 40 6 26 17 26 0 7 63 0 5 1
2023/202476 6 6 4 1 1 0 12 0 4 3 29 10
2024/202572 1 13 5 33 20 0 0 0 0 0 0 0
Totale 670